RBMS1 and cardiac hypertrophy: To further clarify RBMS1 as a potential therapeutic target for cardiac hypertrophy, mice were administered NTP (5 mg/kg) intraperitoneally, alongside the positive control drug Valsartan (VAL) (10 mg/kg) one week after TAC surgery (Appendix Fig. S11A).